Neutralizing antibody responses 10 months after mild and moderately-severe SARS-CoV-2 infection
Dehgani-Mobaraki, P.; Kamber Zaidi, A.; Porreca, A.; Floridi, A.; Floridi, E.
Show abstract
Improved understanding of immunity offered by the antibodies developed against SARS-CoV-2 is critical. Our study aimed at longitudinal analysis of presence and persistence of neutralizing antibodies over ten months in mild and moderately-severe COVID-19 recovered patients using two immunoassays. Article Summary LineNeutralizing IgG antibody persistency was demonstrated in 63.3% of the subjects (19 out of 30) at ten months post-infection with zero re-infections.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts 96%
- Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes 96%
- Development and Evaluation of Two Rapid Indigenous IgG-ELISA immobilized with ACE-2 Binding Peptides for Detection Neutralizing Antibodies Against SARS-CoV-2 95%
Similar papers in this journal
Similar papers in this journal
- Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama 96%
- SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population 95%
- SARS-CoV-2 viremia precedes an IL6 response in severe COVID-19 patients: results of a longitudinal prospective cohort 95%
Similar papers in this journal
Similar papers in this journal
- Antibody response to SARS-CoV2 among COVID-19 confirmed cases, and correlates with neutralizing assay in a subgroup of patients in Delhi National Capital Region, India 97%
- Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees 95%
- Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.